Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...

Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the ...

Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass ...

Danish drugmaker Novo Nordisk A/S said on Monday it is terminating a recently formed obesity-drug partnership with Hims & ...

Shares of Hims & Hers Health plummeted in premarket trading Monday after Novo Nordisk terminated its partnership with the ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Shares in Novo Nordisk fell as much as 3.5 per cent on Monday after detailed trial data on its experimental obesity drug ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Novo Nordisk, the maker of popular weight loss drugs Wegovy and Ozempic, did not immediately provide detailed reasons for ...

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...